UNIVERSITY OF SOUTHERN CALIFORNIA
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1880-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://startusc.com
Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 12
- Registration Number
- NCT00184028
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
A Study of Irinotecan, Cisplatin and Celebrex in Patients With Metastatic or Unresectable Esophageal Cancer
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 6
- Registration Number
- NCT00183807
- Locations
- 🇺🇸
U.S.C. / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 7
- Registration Number
- NCT00184080
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Continuation Booster Trial After a Vaccine Combining Tyrosinase/GP100/MART-1 Peptides Emulsified With Montanide ISA 51 With or Without GM-CSF for Patients With Melanoma
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-05-21
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 23
- Registration Number
- NCT00184067
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 11
- Registration Number
- NCT00184054
- Locations
- 🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States
Clinical Trial of Gemcitabine and Oxaliplatin in Recurrent or Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 7
- Registration Number
- NCT00159458
- Locations
- 🇺🇸
Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Premiere Oncology, Santa Monica, California, United States
Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 1
- Registration Number
- NCT00159471
- Locations
- 🇺🇸
U.S.C / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Capecitabine and Gemcitabine in Patients With Metastatic Colorectal Cancer
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-22
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 53
- Registration Number
- NCT00159445
- Locations
- 🇺🇸
U.S.C./Norris Comprehensive Cancer Center, Los Angeles, California, United States
Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 75
- Registration Number
- NCT00159484
- Locations
- 🇺🇸
U.S.C./Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-07-29
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 63
- Registration Number
- NCT00159432
- Locations
- 🇺🇸
U.S.C./Norris Comprehensive Cancer Center, Los Angeles, California, United States